Summary

Single-organ metastasis and a low TN status (especially in combination), limited local metastasis, and active anticancer treatment are prognostic for a longer overall survival in patients with stage IV non–small cell lung cancer, according to a retrospective analysis using the National Cancer Registry in The Netherlands. Overall survival is longer in patients whose disease is staged using 18-fluoro-deoxyglucose positron emission tomography imaging.